Brief: Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic
17/03/2026 11:51
March 17 (Reuters) - HCW Biologics Inc HCWB.O: HCW BIOLOGICS CLOSES EXCLUSIVE WORLDWIDE LICENSE FOR HCW11-006 – A HIGH POTENTIAL FUSION IMMUNOTHERAPEUTIC HCW BIOLOGICS INC - RECEIVES $7.0 MILLION UPFRONT LICENSE FEE FROM BEIJING TRIMMUNE BIOTECH HCW BIOLOGICS INC - HAS FREE OPTION TO RECLAIM AMERICAS RIGHTS Source text: ID:nGNXcc37Tx Further company coverage: HCWB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hcw Biologics
See all newsBrief: Hcw Biologics Maintains Momentum Toward Completion Of Ind Application For Clinical Study To Evaluate Lead T-Cell Engager In Solid Tumors
Brief: HCW Biologics Registers Resale Of Up To 1.81 Mln Shares Of Common Stock By Selling Stockholder- SEC Filing
NASDAQ RESUMED AT 10:34 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:29 AM
NASDAQ RESUMED AT 10:29 AM